ClinicalTrials.Veeva

Find clinical trials for Glioblastoma (GBM) in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Glioblastoma
Recurrence
Glioma
Brain Cancer
Astrocytoma
Cancer
Gliosarcoma

Glioblastoma (GBM) trials near Boston, MA, USA:

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma...

Active, not recruiting
Glioblastoma
Drug: Temozolomide
Biological: INO-5401

Phase 1, Phase 2

Inovio Pharmaceuticals
Inovio Pharmaceuticals

Boston, Massachusetts, United States and 20 other locations

trial will evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of 8 mg ITI-1001 in participants with newly diagnosed glioblastoma...

Active, not recruiting
Glioblastoma
Drug: ITI-1001

Phase 1

Immunomic Therapeutics

Boston, Massachusetts, United States

A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)...

Active, not recruiting
Glioblastoma Multiforme
Drug: ACP-196

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Boston, Massachusetts, United States and 6 other locations

The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM...

Active, not recruiting
Glioblastoma
Glioblastoma Multiforme
Drug: Dendritic cell immunotherapy

Phase 3

Northwest Biotherapeutics
Northwest Biotherapeutics

Boston, Massachusetts, United States and 85 other locations

Part 1 is an open-label, single-arm, dose escalation study of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment. Evaluate safety and to...

Active, not recruiting
Glioblastoma
Recurrent Glioblastoma
Drug: MN-166
Drug: Temozolomide

Phase 1, Phase 2

MediciNova

Boston, Massachusetts, United States

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....

Enrolling
Glioblastoma
Biological: ADI-PEG 20
Drug: VT1021

Phase 2, Phase 3

Global Coalition for Adaptive Research

Boston, Massachusetts, United States and 60 other locations

with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.The names of the study drugs involved in this study are:Niv...

Active, not recruiting
Glioblastoma
Glioblastoma Multiforme
Drug: Nivolumab-Placebo
Drug: Nivolumab

Phase 1

Patrick Wen, MD

Boston, Massachusetts, United States and 3 other locations

as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma...

Enrolling
Glioblastoma
Drug: RO7428731

Phase 1

Roche
Roche

Boston, Massachusetts, United States and 11 other locations

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change)....

Active, not recruiting
Brain Neoplasms
Other: Nivolumab Placebo
Drug: Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Boston, Massachusetts, United States and 122 other locations

The purpose of this first-in-human (FIH) study of [177Lu]-NeoB is to characterize the safety, tolerability, pharmacokinetics (PK) as well as the dist...

Enrolling
Neoplasms
Drug: [68Ga]-NeoB
Drug: [177Lu]-NeoB

Phase 1, Phase 2

Advanced Accelerator Applications

Providence, Rhode Island, United States and 12 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems